Sangamo Therapeutics Inc (SGMO) CFO Kathy Yi Sells 5,000 Shares

Sangamo Therapeutics Inc (NASDAQ:SGMO) CFO Kathy Yi sold 5,000 shares of the stock in a transaction that occurred on Monday, October 15th. The shares were sold at an average price of $13.97, for a total transaction of $69,850.00. Following the completion of the transaction, the chief financial officer now owns 12,250 shares in the company, valued at $171,132.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Kathy Yi also recently made the following trade(s):

  • On Monday, September 17th, Kathy Yi sold 5,000 shares of Sangamo Therapeutics stock. The shares were sold at an average price of $14.66, for a total transaction of $73,300.00.
  • On Thursday, August 16th, Kathy Yi sold 5,000 shares of Sangamo Therapeutics stock. The shares were sold at an average price of $15.39, for a total transaction of $76,950.00.

Shares of SGMO opened at $14.19 on Friday. The company has a debt-to-equity ratio of 0.07, a current ratio of 7.24 and a quick ratio of 7.24. Sangamo Therapeutics Inc has a 12-month low of $11.30 and a 12-month high of $27.50.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). The business had revenue of $21.42 million for the quarter, compared to analysts’ expectations of $21.43 million. Sangamo Therapeutics had a negative return on equity of 26.36% and a negative net margin of 105.65%. The business’s revenue was up 159.6% on a year-over-year basis. During the same quarter last year, the business posted ($0.17) earnings per share. As a group, analysts expect that Sangamo Therapeutics Inc will post -0.69 earnings per share for the current year.

Several equities analysts have commented on the stock. BidaskClub lowered shares of Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, October 9th. Guggenheim assumed coverage on shares of Sangamo Therapeutics in a research note on Tuesday, October 9th. They issued a “buy” rating and a $18.00 price target on the stock. Zacks Investment Research upgraded shares of Sangamo Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 24th. Wedbush reiterated a “hold” rating and issued a $9.00 price target on shares of Sangamo Therapeutics in a research note on Tuesday, July 24th. Finally, ValuEngine lowered shares of Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, September 6th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $21.00.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Peregrine Capital Management LLC grew its position in shares of Sangamo Therapeutics by 0.7% during the third quarter. Peregrine Capital Management LLC now owns 611,493 shares of the biopharmaceutical company’s stock worth $10,365,000 after acquiring an additional 4,430 shares during the last quarter. United Services Automobile Association grew its position in shares of Sangamo Therapeutics by 9.2% during the second quarter. United Services Automobile Association now owns 57,633 shares of the biopharmaceutical company’s stock worth $818,000 after acquiring an additional 4,860 shares during the last quarter. Northern Trust Corp grew its position in shares of Sangamo Therapeutics by 21.0% during the second quarter. Northern Trust Corp now owns 1,287,800 shares of the biopharmaceutical company’s stock worth $18,286,000 after acquiring an additional 223,870 shares during the last quarter. Bain Capital Public Equity Management LLC purchased a new position in shares of Sangamo Therapeutics during the second quarter worth approximately $2,002,000. Finally, Advisors Asset Management Inc. grew its position in shares of Sangamo Therapeutics by 305.3% during the second quarter. Advisors Asset Management Inc. now owns 21,187 shares of the biopharmaceutical company’s stock worth $301,000 after acquiring an additional 15,960 shares during the last quarter. Institutional investors and hedge funds own 63.75% of the company’s stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc focuses on translating science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.

Further Reading: Growth Stocks, What They Are, What They Are Not

Insider Buying and Selling by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply